Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is a biotechnology company with a strong focus on research and development. The company leverages its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs that target viral infections and liver diseases. Based in Watertown, Massachusetts, Enanta is at the forefront of developing novel inhibitors aimed at combating the hepatitis C virus (HCV), among other conditions.
Enanta's portfolio includes several classes of direct-acting antiviral (DAA) inhibitors, such as protease inhibitors, NS5A inhibitors, and nucleotide polymerase inhibitors. These are complemented by a host-targeted antiviral (HTA) inhibitor class specifically designed against cyclophilin. One of the company's most notable achievements is the development of paritaprevir, a lead protease inhibitor that is a key component of AbbVie's approved HCV treatment regimen.
In addition to HCV, Enanta is actively pursuing treatments for other serious conditions. The company has a preclinical program targeting non-alcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage due to fat buildup. Enanta's research also extends to hepatitis B and the respiratory syncytial virus (RSV), broadening its impact on viral and liver diseases.
Enanta operates in partnership with AbbVie, which markets its protease inhibitors, while other promising drug candidates are progressing through the development pipeline. The company's commitment to innovation and strategic collaboration positions it as a significant player in the biotech industry.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced promising results from its Phase 1b study of EDP-514 in chronic hepatitis B virus (HBV) patients. The drug demonstrated safety and tolerability while achieving a mean reduction of HBV RNA of 1 log after 28 days, compared to 0.3 log in the placebo group. The study included 24 patients treated with nucleoside reverse transcriptase inhibitors. EDP-514 showed favorable pharmacokinetics for once-daily dosing, paving the way for combination therapies aimed at achieving functional cures for chronic HBV infection.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q2 2021 results, with total revenue of $20.1 million, down from $27.6 million year-over-year, impacted by the pandemic's effects on HCV sales. R&D expenses rose to $41.5 million from $32.6 million, while G&A expenses increased to $8.3 million. The net loss widened to $22.0 million, or $1.09 per diluted share, compared to $6.0 million, or $0.30 per share, in Q2 2020. Enanta remains well-capitalized with $400.4 million in cash, supporting its ongoing clinical programs in HBV, RSV, and NASH.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced it plans to report its financial results for the fiscal second quarter ending March 31, 2021, after U.S. market close on May 6, 2021. Following the announcement, management will host a conference call at 4:30 p.m. ET to discuss the results and provide updates on the company's R&D pipeline, focusing on treatments for viral infections and liver diseases. Key areas of development include candidates for respiratory syncytial virus, hepatitis B virus, and non-alcoholic steatohepatitis. Enanta's activities are primarily funded through royalties from HCV products developed with AbbVie.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that CEO Jay R. Luly will present at three virtual investor conferences. Key presentations include:
- H.C. Wainwright & Co. Global Life Sciences Conference on March 9, 2021
- 33rd Annual Roth Conference on March 15, 2021, discussing COVID-19 therapies
- Oppenheimer & Co. Healthcare Conference on March 16, 2021
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that Jay R. Luly, Ph.D., its CEO, will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 8:40 am ET. The presentation will be accessible via live webcast on Enanta's website, with a replay available for 90 days. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with clinical candidates for respiratory syncytial virus, hepatitis B, and non-alcoholic steatohepatitis. Their research is funded by royalties from hepatitis C products developed with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q1 2021 results, highlighting a revenue decline to $31.7 million from $52.6 million due to lower HCV sales. R&D expenses increased to $36.7 million, and net loss expanded to $8.3 million, or $0.41 per share. Key pipeline advancements include ongoing Phase 1b trials for HBV drugs EDP-514 and EDP-721, and the Phase 2b study for RSV drug EDP-938. The company expects preliminary data from its HBV trials in Q2 2021 and aims to identify two clinical candidates in respiratory virology this year.
Enanta Pharmaceuticals (NASDAQ:ENTA) will report its fiscal Q1 results on February 8, 2021, after market close. The company's management will host a conference call at 4:30 p.m. ET to discuss the results and provide updates on its R&D pipeline, targeting viral infections and liver diseases. Enanta’s research focuses on diseases like respiratory syncytial virus, hepatitis B, and non-alcoholic steatohepatitis, with funding derived from royalties from its collaboration with AbbVie for hepatitis C virus treatments.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced the appointment of Brendan Luu as Senior Vice President of Business Development, enhancing its leadership team. With over 20 years of experience in the pharmaceutical sector, Luu previously held significant roles at Merck KGaA, focusing on business development strategies. This transition comes as Enanta prepares for a catalyst-rich year, particularly in advancing its pipeline targeting viral infections and liver diseases, including promising candidates for RSV and hepatitis B.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced a pipeline update at the 39th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2021. CEO Jay R. Luly highlighted the launch of EDP-721, a promising oral hepatitis B candidate, and advancements in respiratory syncytial virus (RSV) programs, including an RSV-L inhibitor initiative. Five clinical trials were initiated in 2020, with key data expected from ongoing studies in NASH and HBV in 2021. Enanta aims to achieve a functional cure for HBV and address significant respiratory diseases.
Enanta Pharmaceuticals (NASDAQ:ENTA) has appointed Dr. John P. DeVincenzo as Vice President of Translational Virology. Dr. DeVincenzo, an expert in respiratory viral diseases with over 30 years of experience, will lead Enanta's clinical development programs for respiratory antivirals. His expertise, particularly in respiratory syncytial virus (RSV), is expected to significantly advance the company’s efforts in developing treatments for RSV and other respiratory infections. Enanta’s clinical program includes ongoing trials for EDP-938, which recently showed positive Phase 2a results.
FAQ
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
What is the market cap of Enanta Pharmaceuticals (ENTA)?
What is the focus of Enanta Pharmaceuticals?
Where is Enanta Pharmaceuticals located?
What are some of the diseases Enanta targets?
What is paritaprevir?
Does Enanta collaborate with other companies?
What is Enanta’s approach to drug discovery?
What is NASH?
What are DAAs?
What is an HTA inhibitor?
What makes Enanta significant in the biotech industry?
